
Shockwave Medical (SWAV) Stock Forecast & Price Target
Shockwave Medical (SWAV) Analyst Ratings
Bulls say
Shockwave Medical is positioned for long-term growth with its innovative technology and strong gross margin of 86.8%. The company's recent growth in coronary sales of 46%, driven by increased vessel bed penetration and potential pipeline initiatives, further supports a positive outlook for sustained double-digit revenue growth. This, combined with the potential for reimbursement upside and expansion into the BTK market, makes Shockwave Medical a promising med tech growth company.
Bears say
Shockwave Medical is facing potential challenges in their outpatient coronary IVL reimbursement and experienced a decline in operating margin. Furthermore, the company's recent acquisition of Neovasc may continue to impact them negatively, leading to lowered revenue estimates. As a result, our analyst believes that Shockwave Medical's financial performance may continue to struggle, leading to a negative outlook for their stock.
This aggregate rating is based on analysts' research of Shockwave Medical and is not a guaranteed prediction by Public.com or investment advice.
Shockwave Medical (SWAV) Analyst Forecast & Price Prediction
Start investing in Shockwave Medical (SWAV)
Order type
Buy in
Order amount
Est. shares
0 shares